Innocoll Holdings plc, a specialty pharmaceutical and medical device company, manufactures and sells collagen-based pharmaceutical products and devices in Europe, the Middle East, Asia, and the United States. The company's products comprise CollaGUARD, a transparent bioresorbable collagen film for the prevention of post-operative adhesions in various surgical applications, including digestive, colorectal, gynecological, and urological surgeries in open and laparoscopic approaches; Collatamp Gentamicin surgical implant for the treatment or prevention of post-operative infection; Septocoll, a bioresorbable dual-action collagen sponge for the treatment or prevention of post-operative infection; and RegenePro, a bioresorbable collagen sponge for dental applications. Its product candidates include XaraColl, an implantable and bioresorbable collagen sponge that is in phase III clinical trials for the treatment of post-operative pain relief; and Cogenzia, a topically applied bioresorbable collagen sponge, which is in phase III efficacy trials for the treatment of diabetic foot infections. The company is headquartered in Athlone, Ireland.
Innocoll reports 2Q loss ATHLONE, Ireland (AP) _ Innocoll AG (INNL) on Wednesday reported a loss of $12.8 million in its second quarter. The Athlone, Ireland-based company said it had a loss of 53 cents per share. Losses, adjusted for non-recurring gains, came to 62 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 73 cents per share. The specialty pharmaceutical company posted revenue of $1.3 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $964,000. Innocoll shares have decreased 33 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $5.54, a drop of 57 percent in the last 12 months.
